Holen Sie sich die Stockscreener-App
1.45
2.84%
0.04
Handel nachbörslich:
1.49
0.04
+2.76%
Aclaris Therapeutics Inc Aktie (ACRS) Neueste Nachrichten
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $9.71 Consensus Price Target from Analysts - Defense World
Revenues Not Telling The Story For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Shares Rise 26% - simplywall.st
Aclaris at Goldman Sachs Conference: Strategic Focus on Immuno-inflammatory Pipeline By Investing.com - Investing.com South Africa
Aclaris at Goldman Sachs Conference: Strategic Focus on Immuno-inflammatory Pipeline - Investing.com Australia
Bank of America Corp DE Buys 196,708 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Vitiligo Drugs Market Exclusive Report with Detailed Study Analysis | Dermavant Sciences, Aclaris Therapeutics - newstrail.com
H.C. Wainwright maintains Buy on Aclaris stock, $16 target By Investing.com - Investing.com Canada
Aclaris Therapeutics Approves 2025 Equity Incentive Plan - TipRanks
Aclaris Therapeutics at Jefferies Conference: Strategic Pipeline Advances By Investing.com - Investing.com Canada
Aclaris Therapeutics to Present at Two Major Healthcare Conferences in June 2025 - MSN
Transcript : Aclaris Therapeutics, Inc. Presents at H.C. Wainwright ?HCW@Home? series, May-16-2025 01 - marketscreener.com
Aclaris begins phase 2 trial for atopic dermatitis drug By Investing.com - Investing.com South Africa
Aclaris Therapeutics, Inc. Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis - marketscreener.com
Aclaris begins phase 2 trial for atopic dermatitis drug - Investing.com Australia
Aclaris Therapeutics (ACRS) Begins Phase 2 Trial for Atopic Dermatitis Treatment | ACRS Stock News - GuruFocus
Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis - GlobeNewswire
Two Sigma Investments LP Sells 68,646 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Northern Trust Corp Has $434,000 Stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates - MSN
What is Wedbush’s Forecast for ACRS Q2 Earnings? - Defense World
Millennium Management LLC Decreases Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics (NASDAQ:ACRS) Coverage Initiated by Analysts at Wedbush - Defense World
Aclaris Therapeutics to Participate in Two June Healthcare Conferences - GlobeNewswire
Aclaris Therapeutics Secures Double Speaking Slots at Major June Healthcare Conferences - Stock Titan
Wedbush sets Aclaris stock Outperform with $8 target By Investing.com - Investing.com India
Wedbush Initiates Coverage of Aclaris Therapeutics (ACRS) with Outperform Recommendation - Nasdaq
Aclaris Therapeutics (ACRS) Receives Outperform Rating from Wedbush | ACRS Stock News - GuruFocus
This Arista Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Aclaris Therapeutics (ACRS) Receives Positive Outlook from Wedbush | ACRS Stock News - GuruFocus
Aclaris Therapeutics (ACRS) Receives Positive Rating from Wedbus - GuruFocus
Wedbush Initiates Aclaris Therapeutics at Outperform With $8 Price Target - marketscreener.com
Costco (COST) Is About to Report Q3 Earnings. Here’s What to Expect - The Globe and Mail
Aclaris Therapeutics (ACRS) Receives Positive Outlook from Wedbu - GuruFocus
Options Volatility and Implied Earnings Moves Today, May 27, 2025 - The Globe and Mail
Prediction: This Will Be the First Mega Technology Company to Split Its Stock in 2025 (and It Isn't Tesla) - The Globe and Mail
Common Warts Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Verrica Pharma, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics, KinoPharma Inc - The Globe and Mail
Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) PT at $10.00 - Defense World
vTv Therapeutics Advances First-in-Class Oral Type 1 Diabetes Drug as New CFO Joins - Stock Titan
HC Wainwright Has Positive Forecast for ACRS Q3 Earnings - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Holdings Raised by Dimensional Fund Advisors LP - Defense World
Aclaris Therapeutics to Host Virtual Fireside Chat with CEO Neal Walker on May 16, 2025 - MSN
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stake Reduced by Price T Rowe Associates Inc. MD - Defense World
Aclaris Therapeutics (ACRS) Price Target Update by HC Wainwright & Co. | ACRS Stock News - GuruFocus
Aclaris Therapeutics (ACRS) Receives Lower Price Target from Ana - GuruFocus
Aclaris Therapeutics Reports Q1 2025 Financial Results - MSN
Androgenetic alopecia Pipeline 2025: Groundbreaking Clinical - openPR.com
Aclaris Therapeutics Reports Q1 2025 Results and Pipeline Updates - MSN
Aclaris Therapeutics Welcomes Dr. Jesse Hall as Chief Medical Officer - MSN
Scotiabank Has Lowered Expectations for Aclaris Therapeutics (NASDAQ:ACRS) Stock Price - Defense World
Aclaris Therapeutics (ACRS) Price Target Lowered by Scotiabank | - GuruFocus
Aclaris Therapeutics First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo
Raymond James Financial Inc. Purchases New Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series - GlobeNewswire
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):